Department of Oncology, Civilian Hospital, Avezzano, Italy.
Oncol Rep. 2012 May;27(5):1377-83. doi: 10.3892/or.2012.1651. Epub 2012 Jan 25.
Chemoembolization with lipiodol (TACE) improves survival of selected patients with unresectable hepatocellular carcinoma (HCC), but results in substantial toxicity. To improve treatment tolerance, we conducted this phase II study using doxorubicin-loaded beads (DC Beads®) delivered by selective transcatheter arterial chemoembolization (DEB-TACE). We compared the results with those obtained with TACE in our historical controls. Thirty-five patients were recruited with diagnoses of HCC. Patients received DEB-TACE with doxorubicin loaded on DC Beads. Computed tomography of the upper abdomen was performed one month after DEB-TACE. Historical controls were a group of 70 patients with matched characteristics treated with TACE. After a median follow-up of 14.1 months (range, 6-36 months), 22 patients (63%) had an objective response. There was a statistically significant decrease in liver enzymes (p<0.001), lactate dehydrogenase, (p<0.001) in DEB-TACE-treated patients compared to TACE-treated patients. DEB-TACE with doxorubicin-loaded DC Beads, a safe and reliable treatment for HCC, leads to decreased toxicity compared to TACE.
碘油化疗栓塞（TACE）可改善不能切除的肝细胞癌（HCC）患者的生存，但会导致严重的毒性。为了提高治疗耐受性，我们进行了这项 II 期研究，使用载多柔比星的微球（DC 微球®）通过选择性经导管动脉化疗栓塞（DEB-TACE）进行给药。我们将结果与我们的历史对照中的 TACE 结果进行了比较。35 名被诊断为 HCC 的患者入组。患者接受载多柔比星的 DC 微球的 DEB-TACE。DEB-TACE 后一个月进行上腹部计算机断层扫描。历史对照是一组 70 名匹配特征的接受 TACE 治疗的患者。中位随访 14.1 个月（范围 6-36 个月）后，22 名患者（63%）有客观反应。与 TACE 治疗组相比，DEB-TACE 治疗组的肝酶（p<0.001）和乳酸脱氢酶（p<0.001）显著下降。与 TACE 相比，载多柔比星的 DC 微球的 DEB-TACE 是一种安全可靠的 HCC 治疗方法，可降低毒性。
